Nightingale Health

Nightingale Health is a global biotechnology company that has pioneered a proprietary, high-throughput blood analysis platform designed to shift healthcare from reactive treatment to proactive chronic disease prevention. At the core of its technology is an advanced proton Nuclear Magnetic Resonance (NMR) metabolomics assay that can simultaneously analyze and quantify 250 metabolic biomarkers from a single, low-volume blood sample (just 100 microliters of serum or plasma). By measuring everything from standard lipids and amino acids to inflammation markers like GlycA and detailed lipoprotein subclasses, Nightingale provides a multi-layered, holistic molecular snapshot of an individual’s current health and future biological vulnerabilities.

Nightingale Health serves as a scalable multiomics hub for global medical research, clinical trials, and population health initiatives, allowing researchers to explore biological mechanisms with unprecedented depth. The platform seamlessly unifies its core metabolomic capabilities with targeted and discovery-based proteomics panels to analyze venous blood, urine, and dried blood matrix types. Because Nightingale’s low-friction, high-fidelity NMR technology preserves sample materials during evaluation, biobanks and healthcare institutions can confidently revisit stored samples over long-term timelines to unlock new omics layers, replicate epidemiological studies, and discover novel therapeutic pathways.

Instead of tracking isolated symptoms after a clinical diagnosis has occurred, Nightingale’s advanced predictive models utilize deep biometric readouts to evaluate multi-disease risk profiles before symptoms manifest. Backed by rigorous peer-reviewed validation across more than 600 scientific publications—including profiling the entire 500,000-sample collection of the UK Biobank—the platform delivers highly predictive risk scores for widespread conditions like cardiovascular disease, type 2 diabetes, and various metabolic disorders. This population-level screening empowers primary care providers and health systems to target preventative lifestyle interventions effectively, lowering overall hospitalization rates and reducing systemic healthcare costs.

Nightingale Health operates a globally scalable, vendor-agnostic infrastructure with laboratories and subsidiaries spanning the United States, Europe, Japan, and Singapore to ensure rapid deployment across diverse medical landscapes. The platform is built to work natively alongside public health agencies, large-scale occupational healthcare networks, and consumer health applications (such as its direct-to-consumer initiative and partnerships with lifestyle platforms like ZOE). By offering both traditional clinical venous testing and the self-collected "Nightingale Kit" for remote, home-based dried blood analysis, the company provides health systems with a flexible framework to easily scale population screening without adding technical friction or workflow strain.